Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody engineering at the millennium.

J V Gavilondo1, J W Larrick

  • 1Center for Genetic Engineering and Biotechnology, Havana, Cuba.

Biotechniques
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models.

Cancer letters·2023
Same author

Contrasting effects of Na+, K+-ATPase activation on seizure activity in acute versus chronic models.

Neuroscience·2015
Same author

Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.

Vaccine·2014
Same author

Clinical trial of a plant-derived antibody on recolonization of mutans streptococci.

Caries research·2005
Same author

Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.

Clinical immunology (Orlando, Fla.)·2001
Same author

Production of secretory IgA antibodies in plants.

Biomolecular engineering·2001
Same journal

Investigating the interactomic landscape of survival motor neuron (SMN) and the SMNΔ7 truncated protein.

BioTechniques·2026
Same journal

Antigen retrieval-immunofluorescence on free floating sections to visualize the liver lobule and its cellular makeup.

BioTechniques·2026
Same journal

Special approach of droplet digital polymerase chain reaction (ddPCR) for transgene stability of a Chinese hamster ovary (CHO) cell line.

BioTechniques·2026
Same journal

Strand-specific quantification of L1 ORF0 and related transcripts by multiplex reverse transcription with tagged primers.

BioTechniques·2026
Same journal

Why and when should we choose digital PCR?

BioTechniques·2026
Same journal

Quantitative and unbiased lung alveolar septum assessment in an LPS experimental mouse model using 2D-spatial correlation image analysis from hematoxylin and eosin slides.

BioTechniques·2026
See all related articles

Recent advances in antibody engineering, including hybridoma technology and PCR, have revolutionized antibody therapeutics. This review covers antibody engineering techniques and their role in developing new drugs and reagents.

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • The discovery of passive immunotherapy and hybridoma technology laid the groundwork for modern antibody therapeutics.
  • Polymerase Chain Reaction (PCR) has been a key technological advancement in the field.
  • Antibodies have evolved from research tools to critical components in disease prevention, detection, and treatment.

Purpose of the Study:

  • To review the advancements in antibody engineering and their impact on therapeutic applications.
  • To highlight key technologies that have driven the renaissance in antibody therapeutics.
  • To discuss the maturation of genetically engineered immunoglobulins as a drug development platform.

Main Methods:

  • Review of historical discoveries and technological milestones in antibody research.

Related Experiment Videos

  • Focus on antibody engineering techniques: chimeric and humanized antibodies, immunoglobulin fragments, antibody libraries, and antibody fusion proteins.
  • Exploration of transgenic organisms as bioreactors for antibody production.

    • Main Results:

    • Recent technological convergence has led to a significant renaissance in antibody therapeutics.
    • Antibody engineering has matured into a sophisticated platform for drug and reagent development.
    • Genetically engineered immunoglobulins are now integral to modern medicine and research.

    Conclusions:

    • Antibody engineering represents a significant leap forward in therapeutic and diagnostic capabilities.
    • The field has evolved from basic research tools to a robust drug development platform.
    • Continued advancements in antibody technology promise further innovations in healthcare.